A new Test for the diagnosis of cervical cancer, is currently causing in the world of medicine for attention. The new Gen-Test recognized in over 15,000 women all cervical cancers and is thus not only more effective but also cheaper than all the major Tests including the cell Smear (Pap Test) and of papilloma virus testing (HPV). The English research team speaks of a revolutionary result.
Researchers at the Queen Mary University of London tested in a clinical Screening study, the effectiveness of a new Gene Tests for the diagnosis of cervical cancer 15.744 women. The spectacular result: The Test detected 100 percent of the cases, the tumor disease. In contrast to other Tests, is searched for in the new method, according to chemical markers in the DNA that identify the cancer clearly. The results of the research were recently published in the “International Journal of Cancer”.
“This is a tremendous development,” emphasizes the lead researcher, Professor Attila Lorincz in a press release of the study results. The researchers were not only surprised at how well this Test of the cervix reveals cancer, but also showed for the first time the key role of epigenetics in cancer diagnostics. “We see increasing evidence that epigenetics are a number of types of cancer in the early stages, including cervical cancer, anal cancer, pharyngeal cancer, colorectal cancer and prostate cancer,” reported the Professor.
The Test could say with the participating women in the development of cervical cancer up to five years in advance. As the researchers report, is carried out the Screening for the prevention of cervical cancer, typically by the Pap smear. This recognize but only in about 50 percent of cases of cervical cancer. The detection rate of new Gene-testing deck against 100 per cent.
The presence of human Papillomavirus (HPV) as a risk factor for the development of cervical cancer. In order to detect whether a Person is infected with HPV, is carried out in the framework of the early detection of an HPV Test. According to the researchers recognize this Test, but only the presence of the virus and not the actual cancer risk will be that in spite of the virus is low stay. This will lead to unnecessary uncertainty for the majority of HPV-infected women.
Professor Lorincz explains that the new Gene Test reduces the number of required screening appointments. “This is really a huge progress that will revolutionize the Screening,” said the expert. Millions of HPV-infected women and men will benefit from this. Also hard-to-detect types of cancer, such as adenocarcinoma could be identified through the Test clearly.
“The new Test is much better than what is currently offered, but it may take at least five years, until he is established,” says Lorincz. The authors do not doubt that this Test will prevail, because it is cheaper and more effective than the Pap smear, and through effective early detection for enormous cost savings. (vb)